Plus, news about Soleno, Novo Nordisk and Cardior Pharmaceuticals:
Royalty Pharma pays Arrowhead Pharmaceuticals: The $50 million milestone payment comes after the completed enrollment of a Phase 3 trial investigating olpasiran in patients with atherosclerotic cardiovascular disease and elevated lipoprotein. Arrowhead could still get another $485 million in milestone payments for the drug. — Katherine Lewin
Abeona prices $75M offering: Adage Capital Partners, Janus Henderson Investors and others bought into the Cleveland-based biotech. Its share price $ABEO was up about 20% Friday morning. The move comes two weeks after the biotech received a CRL for its recessive dystrophic epidermolysis bullosa treatment candidate. — Kyle LaHucik
Soleno prices $138M offering: The California rare disease biotech is selling 3 million shares at $46 apiece. Its share price $SLNO was down more than 3% Friday morning. — Kyle LaHucik
Novo Nordisk completed its $1.1 billion acquisition of German biotech Cardior this week after announcing the deal in March. — Katherine Lewin